Search Results - "Lederer, Emily"

Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma by Badros, Ashraf, Hyjek, Elizabeth, Ma, Ning, Lesokhin, Alexander, Dogan, Ahmet, Rapoport, Aaron P., Kocoglu, Mehmet, Lederer, Emily, Philip, Sunita, Milliron, Todd, Dell, Cameron, Goloubeva, Olga, Singh, Zeba

“…Programmed death 1 (PD-1) receptor and its ligand (PD-L1) facilitate immune evasion in multiple myeloma (MM). We hypothesized that pembrolizumab,…”
Get full text

Racial disparities in multiple myeloma patients with durable stringent complete response by Benyounes, Amin, Ma, Ning, Kocoglu, Mehmet, Patel, Ameet, Rapoport, Aaron, Binion, Katrina, Bosley, Rebecca, Milliron, Todd, Lederer, Emily, Badros, Ashraf

Get full text

A Phase II Study of Anti PD-1 Antibody Pembrolizumab, Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) by Badros, Ashraf Z., Kocoglu, Mehmet H., Ma, Ning, Rapoport, Aaron P., Lederer, Emily, Philip, Sunita, Lesho, Patricia, Dell, Cameron, Hardy, Nancy M., Yared, Jean, Goloubeva, Olga, Singh, Zeba

“…Several recent studies have linked the interactions of programmed death 1 (PD-1) receptor and its ligand (PD-L1) to immunologic control of MM. Expression of…”
Get full text

Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) by Badros, Ashraf Z, Hyjek, Elizabeth, Ma, Ning, Lesokhin, Alexander M., Rapoport, Aaron P., Kocoglu, Mehmet H., Lederer, Emily, Philip, Sunita, Lesho, Patricia, Johnson, Ashlee, Dell, Cameron, Goloubeva, Olga, Singh, Zeba

“…Immunotherapy in MM is emerging as an effective modality in therapy of MM with the approval of several monoclonal antibodies and encouraging results for…”
Get full text

Long-term remissions after stopping pembrolizumab for relapsed or refractory multiple myeloma by Badros, Ashraf Z., Ma, Ning, Rapoport, Aaron P., Lederer, Emily, Lesokhin, Alexander M.

Get full text